A45 Clinical Trial Agreement: Combination Anti-Amyloid Therapy for Preclinical Alzheimer's Disease

A45 Clinical Trial Agreement: Combination Anti-Amyloid Therapy for Preclinical Alzheimer''s Disease The A45 Study targets the preclinical (pre-symptomatic) stage of AD. The study will enroll clinically normal participants (little to no cognitive impairment) who have elevated levels of amyloid in brain and are at high risk for progression to mild cognitive impairment and AD dementia. The A45 Study is a global, multicenter, double-blinded, placebo-controlled, randomized trial of a treatment regimen consisting of an anti-amyloid beta antibody targeted at protofibrils to prevent cognitive decline and delay biomarkers of pathological progression versus placebo. In the active arm, individuals will be treated with high-dose BAN2401 to clear amyloid deposits and Aß protofibrils from the brain, followed by low-dose BAN2401 to prevent re-accumulation of amyloid. The aim of this study is to slow or prevent decline in cognitive performance.